10220
|
ETCTN
|
A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10221
|
ETCTN
|
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in patients with advanced solid tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10222
|
ETCTN
|
A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10231
|
NCORP-National Institutes of Health
|
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
10240
|
ETCTN
|
Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10246
|
ETCTN
|
A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10247
|
ETCTN
|
A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
10249
|
ETCTN
|
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
10250
|
ETCTN
|
A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10264
|
ETCTN
|
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|